Clinical characteristics and outcomes among patients with HF were similar across different waves of the COVID-19 pandemic, according to findings published in International Journal of Cardiology. Theresa McDonagh, MD, and colleagues evaluated all consecutive patients hospitalized for acute HF during three COVID-19 lockdowns. Clinical characteristics, comorbidities, and cardiovascular risk factors were similar, and specialist in-hospital care was continuous, with comparable mortality. While therapy for HF was similar across lockdowns, significantly more patients received angiotensin receptor-neprilysin inhibitors during the second and third lockdowns. A quicker optimization of medical therapy was seen during hospitalizations in later waves.